Briacell Therapeutics 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Briacell Therapeutics 's ROA in the third quarter of 2026?
Briacell Therapeutics Corp recorded a cumulative net loss of $-31 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -111.93%.

However, within the Healthcare sector 807 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Apr 30 2026 quarter, so far to 4398, from total ROA ranking in the second quarter of 2026 at 5131.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Apr 30 2026) III. Quarter	(Jan 31 2026) II. Quarter	(Oct 31 2025) I. Quarter	(Jul 31 2025) IV. Quarter	(Apr 30 2025) III. Quarter
Y / Y Total Assets Change	59.47 %	-21.2 %	30.85 %	80.75 %	187.87 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-31	-30	-29	-27	-20
Return On Assets (TTM)	-111.93 %	-118.8 %	-108.72 %	-102.51 %	-96.46 %
BCTX's Total Ranking	# 4398	# 5131	# 4597	# 4668	# 4746
Total Assets (TTM) in million	26	22	13	50	17
Seq. Total Assets Change	21.57 %	65.58 %	-73.67 %	200.86 %	-39.92 %
Seq. Net Income Change	-	-	-	-	-

BCTX's 5 Years Annual ROA >> Back to BCTX Management Effectiveness >> Compare BCTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 380
Sector	# 808
Overall	# 4353

Return On Assets Statistics
High	Average	Low
-0.89 %	-101.95 %	-201.43 %
(Oct 31 2022)		(Oct 31 2025)

Financial Statements
Briacell Therapeutics 's Assets	$ 26 million	BCTX's Balance sheet
Briacell Therapeutics 's Income	$ -7 million	Quarterly BCTX's Income Statement
BCTX's Income by Division		See BCTX's Income by Division

Annual Return On Assets	(Jul 31 2025) FY 2025	(Jul 31 2024) FY 2024	(Jul 31 2023) FY 2023	(Jul 31 2022) FY 2022	(Jul 31 2021) FY 2021
Y / Y Total Assets Change	80.75 %	-26.68 %	-31.37 %	-57 %	-
Total Assets in million	50	27	37	55	127
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-27	-5	-20	-27	0
Annual Return On Assets	-53.48 %	-17.95 %	-54.18 %	-49.15 %	-0.34 %

BCTX's 5 Years Annual ROA >> Back to BCTX Management Effectiveness >> Compare BCTX ROA to its Competitors

More Return On Assets Ratios
BCTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BCTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BCTX's Competitors
Subscribers only: Roa for Briacell Therapeutics 's Suppliers
Subscribers only: Return On Assets for BCTX's Customers

You may also want to know
BCTX's Roi	BCTX's Inventory Turnover Ratio	BCTX's Growth Rates	BCTX's Dividend Comparisons
	BCTX's Profitability Ratios	BCTX's Asset Turnover Ratio	BCTX's Dividend Growth
BCTX's Roe	BCTX's Valuation Ratios	BCTX's Financial Strength Ratios	BCTX's Dividend Payout Ratio

Companies with similar Return On Assets at Apr 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-17T09:32:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.